ADMA Biologics Inc vs Carparts.Com Inc — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.18B), while Carparts.Com Inc trades at $6.41 (market cap $52.07M). The key difference: ADMA Biologics Inc is far larger — about 41.9× Carparts.Com Inc's market cap, and Carparts.Com Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | PRTS | |
|---|---|---|
Market Cap | $2.18B | $52.07M |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $11.40 |
52-Week Low | $7.60 | $3.88 |
Enterprise Value | $2.25B | $67.05M |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
CarParts.com (PRTS) is trading at $6.75, up 16.68% with bullish technical signals and strong analyst support. The company shows improving operational performance with three consecutive quarterly earnings beats, though it remains unprofitable with negative net margins. Recent developments include a 10:1 reverse stock split completed in May 2026 and a new $25 million credit facility, providing financial flexibility amid challenging market conditions.
The outlook remains cautiously optimistic with 60% analyst buy ratings supporting recovery potential, but significant risks persist from sustained losses, negative cash flow, and competitive pressures. Investors should focus on the company's ability to leverage proprietary data advantages while monitoring progress toward profitability in the competitive auto parts e-commerce sector.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
Read more on PRTS →